Jason Westin
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jason Westin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06213311 · A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaM.D. Anderson Cancer Center · recruiting · B Cell Lymphoma · principal investigator
- Ph2NCT05615636 · A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLM.D. Anderson Cancer Center · recruiting · Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL · principal investigator
- N/ANCT05464823 · Feasibility of Combined Genomics/Transcriptomics for Patients With LymphomaM.D. Anderson Cancer Center · active not recruiting · Lymphoma · principal investigator
- Ph2NCT04978584 · Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyM.D. Anderson Cancer Center · active not recruiting · Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT03770416 · Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaM.D. Anderson Cancer Center · completed · Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma · principal investigator
- Ph2NCT02636322 · Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibM.D. Anderson Cancer Center · completed · Diffuse Large B-Cell Lymphoma Unclassifiable · principal investigator
- Early Ph1NCT02405078 · Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaM.D. Anderson Cancer Center · completed · Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 112 PubMed records, and a shared surname and initials can bring in a namesake. All 112 on PubMed
- 5,007 citationsRCR 162.2
- 3,432 citationsRCR 128.5
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J Med · 20221,394 citationsRCR 94.5
- 524 citationsRCR 26.6
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med · 2022459 citationsRCR 30.2
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.Lancet Oncol · 2014438 citationsRCR 11.6
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.N Engl J Med · 2023428 citationsRCR 35.5
- 260 citationsRCR 6.4
- 224 citationsRCR 6.1
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Lancet Oncol · 2014217 citationsRCR 5.9